DK2234617T3 - Doseringsskema forbundet med langtidsvirkende injicerbare paliperidonestere - Google Patents
Doseringsskema forbundet med langtidsvirkende injicerbare paliperidonestere Download PDFInfo
- Publication number
- DK2234617T3 DK2234617T3 DK08863534.7T DK08863534T DK2234617T3 DK 2234617 T3 DK2234617 T3 DK 2234617T3 DK 08863534 T DK08863534 T DK 08863534T DK 2234617 T3 DK2234617 T3 DK 2234617T3
- Authority
- DK
- Denmark
- Prior art keywords
- paliperidones
- injective
- term
- long
- dosage schedule
- Prior art date
Links
- 230000007774 longterm Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L31/00—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof
- H01L31/08—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof in which radiation controls flow of current through the device, e.g. photoresistors
- H01L31/10—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof in which radiation controls flow of current through the device, e.g. photoresistors characterised by potential barriers, e.g. phototransistors
- H01L31/101—Devices sensitive to infrared, visible or ultraviolet radiation
- H01L31/102—Devices sensitive to infrared, visible or ultraviolet radiation characterised by only one potential barrier
- H01L31/109—Devices sensitive to infrared, visible or ultraviolet radiation characterised by only one potential barrier the potential barrier being of the PN heterojunction type
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Computer Hardware Design (AREA)
- Microelectronics & Electronic Packaging (AREA)
- Power Engineering (AREA)
- Dermatology (AREA)
- Electromagnetism (AREA)
- Manufacturing & Machinery (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1491807P | 2007-12-19 | 2007-12-19 | |
US12027608P | 2008-12-05 | 2008-12-05 | |
PCT/EP2008/067738 WO2009080651A1 (en) | 2007-12-19 | 2008-12-17 | Dosing regimen associated with long acting injectable paliperidone esters |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2234617T3 true DK2234617T3 (da) | 2021-05-25 |
Family
ID=40428256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08863534.7T DK2234617T3 (da) | 2007-12-19 | 2008-12-17 | Doseringsskema forbundet med langtidsvirkende injicerbare paliperidonestere |
Country Status (26)
Country | Link |
---|---|
US (3) | US9439906B2 (da) |
EP (2) | EP3909585A1 (da) |
JP (1) | JP5825786B2 (da) |
KR (3) | KR20100099292A (da) |
CN (2) | CN101932327A (da) |
AU (2) | AU2008340101B2 (da) |
BR (1) | BRPI0821408A2 (da) |
CO (1) | CO6300949A2 (da) |
CY (1) | CY1124103T1 (da) |
DK (1) | DK2234617T3 (da) |
EA (1) | EA020697B1 (da) |
EC (1) | ECSP10010289A (da) |
ES (1) | ES2868353T3 (da) |
GT (1) | GT201000182A (da) |
HK (1) | HK1223850A1 (da) |
HR (1) | HRP20210669T1 (da) |
HU (1) | HUE053904T2 (da) |
IL (2) | IL206448A (da) |
LT (1) | LT2234617T (da) |
NI (1) | NI201000105A (da) |
NZ (1) | NZ586221A (da) |
PL (1) | PL2234617T3 (da) |
PT (1) | PT2234617T (da) |
RS (1) | RS61765B1 (da) |
SI (1) | SI2234617T1 (da) |
WO (1) | WO2009080651A1 (da) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
US9439906B2 (en) * | 2007-12-19 | 2016-09-13 | Janssen Pharmaceutica Nv | Dosing regimen associated with long acting injectable paliperidone esters |
US8758780B2 (en) * | 2009-10-06 | 2014-06-24 | Ascendis Pharma As | Subcutaneous paliperidone composition |
US20130053405A1 (en) * | 2009-10-06 | 2013-02-28 | Ulrich Hersel | Carrier linked paliperidone prodrugs |
NZ599558A (en) * | 2009-10-30 | 2014-09-26 | Janssen Pharmaceutica Nv | Dosing regimen associated with long-acting injectable paliperidone esters |
WO2011114213A1 (en) | 2010-03-15 | 2011-09-22 | Inventia Healthcare Private Limited | Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic |
US9522980B2 (en) | 2010-05-06 | 2016-12-20 | Johnson & Johnson Vision Care, Inc. | Non-reactive, hydrophilic polymers having terminal siloxanes and methods for making and using the same |
TWI577377B (zh) * | 2010-09-16 | 2017-04-11 | Viiv醫療保健公司 | 醫藥組合物 |
US9034867B2 (en) * | 2011-03-18 | 2015-05-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising sorbitan esters |
US9170349B2 (en) | 2011-05-04 | 2015-10-27 | Johnson & Johnson Vision Care, Inc. | Medical devices having homogeneous charge density and methods for making same |
DK2529756T3 (da) | 2011-05-31 | 2021-08-02 | Farm Rovi Lab Sa | Risperidon- og/eller paliperidon-implantatformulering |
SI2529757T1 (sl) | 2011-05-31 | 2014-05-30 | Laboratorios Farmaceuticos Rovi, S.A. | Formulacija paliperidon implantata |
CN102274164B (zh) * | 2011-08-22 | 2014-07-02 | 长春健欣生物医药科技开发有限公司 | 帕潘立酮及帕潘立酮衍生物的注射用缓释凝胶剂 |
CN103301461B (zh) * | 2012-03-08 | 2018-09-07 | 江苏豪森药业集团有限公司 | 一种长效注射制剂及其制备方法和用途 |
CA2867137C (en) | 2012-03-19 | 2020-12-08 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol |
JP6219918B2 (ja) | 2012-03-19 | 2017-10-25 | アルカームス ファーマ アイルランド リミテッド | グリセロールエステルを含む医薬組成物 |
NZ630643A (en) | 2012-03-19 | 2017-08-25 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising fatty acid esters |
US10073192B2 (en) | 2012-05-25 | 2018-09-11 | Johnson & Johnson Vision Care, Inc. | Polymers and nanogel materials and methods for making and using the same |
US9244196B2 (en) | 2012-05-25 | 2016-01-26 | Johnson & Johnson Vision Care, Inc. | Polymers and nanogel materials and methods for making and using the same |
US9193685B2 (en) | 2012-09-19 | 2015-11-24 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
AU2015231278B2 (en) | 2014-03-20 | 2020-01-23 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
WO2016032950A1 (en) | 2014-08-25 | 2016-03-03 | Alkermes Pharma Ireland Limited | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia |
US9844551B2 (en) | 2015-01-14 | 2017-12-19 | Children's Hospital Medical Center | Compositions and methods for treatment of fragile X syndrome |
US10441580B2 (en) * | 2015-02-17 | 2019-10-15 | Vanda Pharmaceuticals, Inc. | Iloperidone for the treatment of schizophrenia |
WO2016157061A1 (en) | 2015-03-31 | 2016-10-06 | Wockhardt Limited | Aseptic wet milling process for paliperidone palmitate |
NZ735952A (en) | 2015-04-07 | 2022-02-25 | Janssen Pharmaceutica Nv | Dosing regimen for missed doses for long-acting injectable paliperidone esters |
EP3544593A4 (en) * | 2016-11-23 | 2020-11-25 | Children's Hospital Medical Center | PALIPERIDONE FOR THE TREATMENT OF DRUG REFRACTORY IRRITABILITY AND AUTISTIC SPECTRUM DISORDER |
AU2018354431B2 (en) * | 2017-10-27 | 2024-01-18 | Geneora Pharma (Shijiazhuang) Co., Ltd. | Dosage regimen of paliperidone palmitate extended-release injectable suspension |
JP7384812B2 (ja) | 2018-03-05 | 2023-11-21 | アルカームス ファーマ アイルランド リミテッド | アリピプラゾール投与戦略 |
CN110279659A (zh) * | 2019-07-08 | 2019-09-27 | 华裕(无锡)制药有限公司 | 棕榈酸帕利哌酮制剂及其制备方法 |
GR1009869B (el) * | 2019-07-12 | 2020-11-12 | Φαρματεν Α.Β.Ε.Ε. | Ενεσιμο παρατεταμενης αποδεσμευσης φαρμακευτικο σκευασμα που περιλαμβανει παλμιτικη παλιπεριδονη και μεθοδος παρασκευης αυτου |
US11583521B2 (en) * | 2020-07-01 | 2023-02-21 | Jubilant Pharma Holdings Inc. | Long-acting injection dosage form of beta 3 adrenoreceptor agonists |
IL303252A (en) | 2020-11-30 | 2023-07-01 | Janssen Pharmaceutica Nv | Dosing regimens associated with delayed-release injectable formulations of paliperidone |
PT4025188T (pt) | 2020-11-30 | 2024-02-29 | Janssen Pharmaceutica Nv | Regimes de administração associados a formulações injetáveis de paliperidona de libertação prolongada |
EP4005555B1 (en) | 2020-11-30 | 2024-05-15 | Janssen Pharmaceutica NV | Methods for ensuring resuspension of paliperidone palmitate formulations |
EP4025187B1 (en) | 2020-11-30 | 2024-01-03 | Janssen Pharmaceutica NV | Dosing regimens associated with extended release paliperidone injectable formulations |
RU2756614C1 (ru) * | 2021-04-07 | 2021-10-04 | Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук» (Томский НИМЦ) | Способ поддержки принятия врачебных решений выбора антипсихотической терапии у больных шизофренией с целью профилактики акатизии |
CN118119394A (zh) | 2021-08-20 | 2024-05-31 | 詹森药业有限公司 | 与延长释放帕潘立酮可注射制剂相关的给药方案 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1491807A (en) | 1922-06-20 | 1924-04-29 | John P Mclinn | Traveling bag |
US1491809A (en) | 1923-02-17 | 1924-04-29 | Us Fireworks Mfg Company Inc | Toy |
US4804663A (en) * | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
US5254556A (en) * | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
US5158952A (en) * | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
TW376319B (en) * | 1993-04-28 | 1999-12-11 | Janssen Pharmaceutica Nv | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine |
US5453425A (en) * | 1994-07-11 | 1995-09-26 | Janssen Pharmaceutica N.V. | Risperidone oral formulation |
TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
UA72189C2 (uk) * | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
US6342488B1 (en) * | 1998-08-18 | 2002-01-29 | Sepracor, Inc. | Phosphonorisperidone and sulforisperidone compositions and methods |
KR100338776B1 (ko) | 2000-07-11 | 2002-05-31 | 윤종용 | 멀티 로우 어드레스 테스트 가능한 반도체 메모리 장치 및그 테스트 방법 |
RU2321391C2 (ru) * | 2002-07-29 | 2008-04-10 | Алза Корпорейшн | Способы и лекарственные формы для контролируемой доставки палиперидона |
WO2004018312A1 (en) | 2002-08-21 | 2004-03-04 | Pharmacia Corporation | Injectable pharmaceutical suspension in a two-chamber vial |
US20060079846A1 (en) | 2004-10-08 | 2006-04-13 | Alton Williams | Hypodermic syringes with multiple needles and methods of calming psychiatric patients using such |
US20080214808A1 (en) * | 2005-04-25 | 2008-09-04 | Thomas Frederik Ernestine Spittaels | Preparation of Aseptic 3-[2-[4-((6-Fluoro-1,2-Benzisoxazol-3-Yl)-1-Piperidinyl]-6,7,8,9-Tetrahydro-9-Hydroxy-2-Methyl-4H-Pyrido[1,2-a]Pyrimidin-4-One Palmitate Ester |
US20070197591A1 (en) * | 2005-12-12 | 2007-08-23 | Sandra Boom | Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function |
US20070232624A1 (en) * | 2006-04-03 | 2007-10-04 | Palumbo Joseph M | Use of paliperidone for the treatment of sleep disturbances and/or excessive daytime sleepiness in psychiatric patients |
EP1940834A2 (en) | 2006-08-14 | 2008-07-09 | Teva Pharmaceutical Industries Ltd. | Amorphous and crystalline forms of 9-hydroxy-risperidone (paliperidone) |
ATE530170T1 (de) | 2007-08-21 | 2011-11-15 | Teva Pharma | Paliperidonformulierung mit verzögerter freisetzung |
WO2009047499A2 (en) | 2007-10-09 | 2009-04-16 | Cipla Limited | Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes |
US9439906B2 (en) | 2007-12-19 | 2016-09-13 | Janssen Pharmaceutica Nv | Dosing regimen associated with long acting injectable paliperidone esters |
NZ599558A (en) * | 2009-10-30 | 2014-09-26 | Janssen Pharmaceutica Nv | Dosing regimen associated with long-acting injectable paliperidone esters |
US11114549B2 (en) | 2017-11-29 | 2021-09-07 | Taiwan Semiconductor Manufacturing Co., Ltd. | Semiconductor structure cutting process and structures formed thereby |
US11450758B2 (en) | 2020-06-12 | 2022-09-20 | Taiwan Semiconductor Manufacturing Co., Ltd. | Gate structure of semiconductor device and method of forming same |
-
2008
- 2008-12-17 US US12/337,144 patent/US9439906B2/en active Active
- 2008-12-17 RS RS20210495A patent/RS61765B1/sr unknown
- 2008-12-17 EA EA201070757A patent/EA020697B1/ru not_active IP Right Cessation
- 2008-12-17 KR KR1020107015670A patent/KR20100099292A/ko active Search and Examination
- 2008-12-17 KR KR1020177003860A patent/KR102163196B1/ko active IP Right Grant
- 2008-12-17 PL PL08863534T patent/PL2234617T3/pl unknown
- 2008-12-17 EP EP21164550.2A patent/EP3909585A1/en active Pending
- 2008-12-17 NZ NZ586221A patent/NZ586221A/xx unknown
- 2008-12-17 HU HUE08863534A patent/HUE053904T2/hu unknown
- 2008-12-17 BR BRPI0821408-5A patent/BRPI0821408A2/pt not_active Application Discontinuation
- 2008-12-17 ES ES08863534T patent/ES2868353T3/es active Active
- 2008-12-17 PT PT88635347T patent/PT2234617T/pt unknown
- 2008-12-17 LT LTEP08863534.7T patent/LT2234617T/lt unknown
- 2008-12-17 CN CN2008801261088A patent/CN101932327A/zh active Pending
- 2008-12-17 DK DK08863534.7T patent/DK2234617T3/da active
- 2008-12-17 CN CN201610011987.6A patent/CN105560176A/zh active Pending
- 2008-12-17 SI SI200832163T patent/SI2234617T1/sl unknown
- 2008-12-17 KR KR1020197012533A patent/KR102318070B1/ko active IP Right Grant
- 2008-12-17 JP JP2010538703A patent/JP5825786B2/ja active Active
- 2008-12-17 WO PCT/EP2008/067738 patent/WO2009080651A1/en active Application Filing
- 2008-12-17 EP EP08863534.7A patent/EP2234617B1/en active Active
- 2008-12-17 AU AU2008340101A patent/AU2008340101B2/en active Active
-
2010
- 2010-06-17 IL IL206448A patent/IL206448A/en unknown
- 2010-06-18 GT GT201000182A patent/GT201000182A/es unknown
- 2010-06-18 EC EC2010010289A patent/ECSP10010289A/es unknown
- 2010-06-18 NI NI201000105A patent/NI201000105A/es unknown
- 2010-06-23 CO CO10075713A patent/CO6300949A2/es not_active Application Discontinuation
-
2015
- 2015-02-18 AU AU2015200801A patent/AU2015200801B2/en active Active
-
2016
- 2016-08-25 US US15/247,149 patent/US20170128451A1/en not_active Abandoned
- 2016-10-26 HK HK16112292.2A patent/HK1223850A1/zh unknown
-
2017
- 2017-07-13 IL IL253468A patent/IL253468A0/en unknown
-
2018
- 2018-01-25 US US15/880,160 patent/US20180147210A1/en not_active Abandoned
-
2021
- 2021-04-27 HR HRP20210669TT patent/HRP20210669T1/hr unknown
- 2021-05-12 CY CY20211100404T patent/CY1124103T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2234617T3 (da) | Doseringsskema forbundet med langtidsvirkende injicerbare paliperidonestere | |
NO2022056I1 (no) | avalglucosidase alfa | |
DK2479264T3 (da) | Glucoamylasevarianter med ændrede egenskaber | |
DK2099453T3 (da) | Kombinationsterapi med substituerede oxazolidinoner | |
DK2527713T3 (da) | Blender med stigningsgrad | |
BRPI0720699A2 (pt) | Programas ligados | |
DK2029458T3 (da) | Kapsel med mindsket dryppen | |
DK2479265T3 (da) | Glucoamylasevarianter med ændrede egenskaber | |
DK2139987T3 (da) | Fremgangsmåder til proteinfremstilling med anti-senescens-forbindelser | |
DK2245130T3 (da) | Ts23 -alpha-amylasevarianter med ændrede egenskaber | |
DK2106215T3 (da) | Brød med forhøjet arabinoxylo-oligosaccharid-indhold | |
DK2182863T3 (da) | Åbningsdilatator | |
BRPI1006175A2 (pt) | composição agroquímica estabilizada | |
DK2280734T3 (da) | Faktor-ix-konjugater med forlængede halveringstider | |
BRPI1013030A2 (pt) | "aquecedores" | |
DK2125048T3 (da) | Præparat | |
DK2131818T3 (da) | Ny doseringsform | |
BRPI0818598A2 (pt) | agentes terapêuticos - 802 | |
DK1927646T3 (da) | Odoriseringsmiddel med forbedret stabilitet | |
DE502007002482D1 (de) | Injektor | |
DK2236023T3 (da) | Stald med gulvelement | |
DK2152881T3 (da) | RumC-peptider med antimikrobiel aktivitet | |
DK2257292T3 (da) | Kombinationsterapi med Zn/trimethoprim | |
BRPI0807654A2 (pt) | Terapia com vacinas para a neovascularização de coroide | |
DK1970496T3 (da) | Doseringsarrangement |